Get the Stockscreener App
7.75
1.29%
0.05
After Hours:
7.78
0.03
+0.39%
Precigen Inc stock is traded at $7.75, with a volume of 5.97M.
It is up +1.29% in the last 24 hours and up +7.13% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$7.70
Open:
$8.08
24h Volume:
5.97M
Relative Volume:
1.20
Market Cap:
$2.77B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-5.5365
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+0.25%
1M Performance:
+7.13%
6M Performance:
+151.59%
1Y Performance:
+123.79%
1-Day Range:
$7.63
$8.27
1-Week Range:
$7.19
$8.27
52-Week Range:
$2.99
$8.27
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
7.75 | 2.76B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
526.44 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
787.33 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.89 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.61 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.05 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - Yahoo Finance
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies - Yahoo Finance
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target - TradingView
Precigen stock hits 52-week high at 8.05 USD - Investing.com
$Precigen (PGEN.US)$ ready for the next leg higher - Moomoo
PGEN Initiates Coverage On B. Riley Securities -- Rating Set to Buy - GuruFocus
B.Riley initiates Precigen stock coverage with buy on drug launch By Investing.com - Investing.com South Africa
B.Riley initiates Precigen stock coverage with buy on drug launch - Investing.com Canada
Form 4 Precigen Inc For: 25 September - Investing.com India
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com UK
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? - Yahoo Finance UK
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Precigen's AdenoVerse Receives FDA Platform Technology Designation - marketscreener.com
PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
FDA grants platform technology status to Precigen’s AdenoVerse - Investing.com
September 2026's Leading Growth Companies With Insider Backing - simplywall.st
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform - TradingView
Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base - finance.yahoo.com
Precigen, Inc. (PGEN) Stock Analysis: A 84% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Precigen stock hits 52-week high at 7.74 USD By Investing.com - Investing.com Nigeria
Precigen stock hits 52-week high at 7.74 USD - Investing.com
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? - finance.yahoo.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? - Yahoo Finance
Precigen Insider Sold Shares Worth $1,376,400, According to a Recent SEC Filing - Yahoo Finance
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares - GuruFocus
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Australia
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy? - Yahoo Finance
Is Precigen (PGEN) Undervalued After Reaching Quarterly Profitability? - sahmcapital.com
Precigen director Jeffrey Kindler sells $1.38m in stock - Investing.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com South Africa
Precigen CCO Phil Tennant sells $593,745 in stock By Investing.com - Investing.com Nigeria
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing - marketscreener.com
Precigen (PGEN) insider lines up another stock sale after four recent trades - Stock Titan
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026 - Stock Titan
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Investing News Network
3 Growth Companies With High Insider Ownership And 55% Earnings Growth - Sahm
Precigen (PGEN) officer targets $259,935 insider stock sale - Stock Titan
Precigen (NASDAQ:PGEN) Trading Down 3.6%Here's Why - MarketBeat
$Precigen (PGEN.US)$ keep it up! - Moomoo
Precigen (NASDAQ:PGEN) Hits New 12-Month HighTime to Buy? - MarketBeat
Precigen stock hits 52-week high at 7.33 USD By Investing.com - Investing.com Australia
Reasons Why Investors Should Consider Betting on PGEN Stock - TradingView
Precigen (PGEN) Stock: Ends Up by 6.30% at $7.17 in the Latest Session; Key Range: Support at $6.81 and Resistance at $7.53 Frame the Range under the Current SnapshotPut Spread Alert - vinanet.vn
Stock Traders Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat
Alpine Woods Capital Investors LLC Takes $1.31 Million Position in Precigen, Inc. $PGEN - MarketBeat
$Precigen (PGEN.US)$ DCA'd Up. Ready for the next leg higher - Moomoo
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KINDLER JEFFREY B | Director |
Aug 26 '26 |
Sale |
7.44 |
185,000 |
1,376,400 |
17,100 |
3.02%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):